TG Therapeutics (NASDAQ:TGTX) had its price objective hosited by MLV & Co. from $9.00 to $11.00 in a report released on Friday, AR Network reports. MLV & Co. currently has a buy rating on the stock.
Shares of TG Therapeutics (NASDAQ:TGTX) traded down 5.51% on Friday, hitting $6.52. The stock had a trading volume of 153,605 shares. TG Therapeutics has a 1-year low of $2.97 and a 1-year high of $7.75. The stock’s 50-day moving average is $5.89 and its 200-day moving average is $4.94. The company’s market cap is $218.4 million.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.01. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $40.00 million. Analysts expect that TG Therapeutics will post $-0.84 EPS for the current fiscal year.